Inactivation of the p16INK4A gene by methylation is not a frequent event in sporadic ovarian carcinoma

Iain Brown, Benedict Jon Milner, Patrick Hugh Rooney, Neva Elizabeth Haites

Research output: Contribution to journalArticle

15 Citations (Scopus)

Abstract

The p16(INK4A) tumour suppressor gene (p16) encodes for a cyclin-dependant kinase inhibitor which plays a role in the phosphorylation of the retinoblastoma protein (pRb) during regulation of the GI-S phase of the cell cycle. Loss of heterozygosity at 9p21, the chromosomal location of the p16 gene, has been reported in a broad range of tumours. and this is usually indicative of the presence of a tumour suppressor gene, the second allele being frequently inactivated by mutation or deletion. The p16 gene, however, is often found not be mutated or deleted and it has been suggested that hypermethylation of the CpG islands of the gene may be an alternative mechanism of gene inactivation. We sought to determine the levels of p16 abnormality in a series of epithelial ovarian carcinomas in an attempt to clarify the presently conflicting evidence of whether or not hypermethylation of the p16 gene plays a role in ovarian carcinogenesis. We analysed 57 primary ovarian tumours and their corresponding blood DNA using SSCP analysis, sequencing and the methylation specific PCR (MSP) technique. We found low levels of mutation (6.7% of malignant tumours) and no evidence of methylation in any of our samples, suggesting that neither mutation or hypermethylation of the CpG islands of the p16 gene play an important role in ovarian carcinogenesis.

Original languageEnglish
Pages (from-to)1359-1362
Number of pages3
JournalOncology Reports
Volume8
Issue number6
Publication statusPublished - 2001

Keywords

  • ovarian cancer
  • tumour suppressor gene
  • p16
  • methylation
  • HUMAN CANCERS
  • DNA METHYLATION
  • P16 GENE
  • MUTATIONS
  • TUMORS
  • HETEROZYGOSITY
  • EXPRESSION
  • MTS1
  • CHROMOSOME-9
  • P16/MTS1

Cite this

Brown, I., Milner, B. J., Rooney, P. H., & Haites, N. E. (2001). Inactivation of the p16INK4A gene by methylation is not a frequent event in sporadic ovarian carcinoma. Oncology Reports, 8(6), 1359-1362.

Inactivation of the p16INK4A gene by methylation is not a frequent event in sporadic ovarian carcinoma. / Brown, Iain; Milner, Benedict Jon; Rooney, Patrick Hugh; Haites, Neva Elizabeth.

In: Oncology Reports, Vol. 8, No. 6, 2001, p. 1359-1362.

Research output: Contribution to journalArticle

Brown, I, Milner, BJ, Rooney, PH & Haites, NE 2001, 'Inactivation of the p16INK4A gene by methylation is not a frequent event in sporadic ovarian carcinoma', Oncology Reports, vol. 8, no. 6, pp. 1359-1362.
Brown, Iain ; Milner, Benedict Jon ; Rooney, Patrick Hugh ; Haites, Neva Elizabeth. / Inactivation of the p16INK4A gene by methylation is not a frequent event in sporadic ovarian carcinoma. In: Oncology Reports. 2001 ; Vol. 8, No. 6. pp. 1359-1362.
@article{aac85a90a6b347d7ab074360c19c5aa8,
title = "Inactivation of the p16INK4A gene by methylation is not a frequent event in sporadic ovarian carcinoma",
abstract = "The p16(INK4A) tumour suppressor gene (p16) encodes for a cyclin-dependant kinase inhibitor which plays a role in the phosphorylation of the retinoblastoma protein (pRb) during regulation of the GI-S phase of the cell cycle. Loss of heterozygosity at 9p21, the chromosomal location of the p16 gene, has been reported in a broad range of tumours. and this is usually indicative of the presence of a tumour suppressor gene, the second allele being frequently inactivated by mutation or deletion. The p16 gene, however, is often found not be mutated or deleted and it has been suggested that hypermethylation of the CpG islands of the gene may be an alternative mechanism of gene inactivation. We sought to determine the levels of p16 abnormality in a series of epithelial ovarian carcinomas in an attempt to clarify the presently conflicting evidence of whether or not hypermethylation of the p16 gene plays a role in ovarian carcinogenesis. We analysed 57 primary ovarian tumours and their corresponding blood DNA using SSCP analysis, sequencing and the methylation specific PCR (MSP) technique. We found low levels of mutation (6.7{\%} of malignant tumours) and no evidence of methylation in any of our samples, suggesting that neither mutation or hypermethylation of the CpG islands of the p16 gene play an important role in ovarian carcinogenesis.",
keywords = "ovarian cancer, tumour suppressor gene, p16, methylation, HUMAN CANCERS, DNA METHYLATION, P16 GENE, MUTATIONS, TUMORS, HETEROZYGOSITY, EXPRESSION, MTS1, CHROMOSOME-9, P16/MTS1",
author = "Iain Brown and Milner, {Benedict Jon} and Rooney, {Patrick Hugh} and Haites, {Neva Elizabeth}",
year = "2001",
language = "English",
volume = "8",
pages = "1359--1362",
journal = "Oncology Reports",
issn = "1021-335X",
publisher = "Spandidos Publications",
number = "6",

}

TY - JOUR

T1 - Inactivation of the p16INK4A gene by methylation is not a frequent event in sporadic ovarian carcinoma

AU - Brown, Iain

AU - Milner, Benedict Jon

AU - Rooney, Patrick Hugh

AU - Haites, Neva Elizabeth

PY - 2001

Y1 - 2001

N2 - The p16(INK4A) tumour suppressor gene (p16) encodes for a cyclin-dependant kinase inhibitor which plays a role in the phosphorylation of the retinoblastoma protein (pRb) during regulation of the GI-S phase of the cell cycle. Loss of heterozygosity at 9p21, the chromosomal location of the p16 gene, has been reported in a broad range of tumours. and this is usually indicative of the presence of a tumour suppressor gene, the second allele being frequently inactivated by mutation or deletion. The p16 gene, however, is often found not be mutated or deleted and it has been suggested that hypermethylation of the CpG islands of the gene may be an alternative mechanism of gene inactivation. We sought to determine the levels of p16 abnormality in a series of epithelial ovarian carcinomas in an attempt to clarify the presently conflicting evidence of whether or not hypermethylation of the p16 gene plays a role in ovarian carcinogenesis. We analysed 57 primary ovarian tumours and their corresponding blood DNA using SSCP analysis, sequencing and the methylation specific PCR (MSP) technique. We found low levels of mutation (6.7% of malignant tumours) and no evidence of methylation in any of our samples, suggesting that neither mutation or hypermethylation of the CpG islands of the p16 gene play an important role in ovarian carcinogenesis.

AB - The p16(INK4A) tumour suppressor gene (p16) encodes for a cyclin-dependant kinase inhibitor which plays a role in the phosphorylation of the retinoblastoma protein (pRb) during regulation of the GI-S phase of the cell cycle. Loss of heterozygosity at 9p21, the chromosomal location of the p16 gene, has been reported in a broad range of tumours. and this is usually indicative of the presence of a tumour suppressor gene, the second allele being frequently inactivated by mutation or deletion. The p16 gene, however, is often found not be mutated or deleted and it has been suggested that hypermethylation of the CpG islands of the gene may be an alternative mechanism of gene inactivation. We sought to determine the levels of p16 abnormality in a series of epithelial ovarian carcinomas in an attempt to clarify the presently conflicting evidence of whether or not hypermethylation of the p16 gene plays a role in ovarian carcinogenesis. We analysed 57 primary ovarian tumours and their corresponding blood DNA using SSCP analysis, sequencing and the methylation specific PCR (MSP) technique. We found low levels of mutation (6.7% of malignant tumours) and no evidence of methylation in any of our samples, suggesting that neither mutation or hypermethylation of the CpG islands of the p16 gene play an important role in ovarian carcinogenesis.

KW - ovarian cancer

KW - tumour suppressor gene

KW - p16

KW - methylation

KW - HUMAN CANCERS

KW - DNA METHYLATION

KW - P16 GENE

KW - MUTATIONS

KW - TUMORS

KW - HETEROZYGOSITY

KW - EXPRESSION

KW - MTS1

KW - CHROMOSOME-9

KW - P16/MTS1

M3 - Article

VL - 8

SP - 1359

EP - 1362

JO - Oncology Reports

JF - Oncology Reports

SN - 1021-335X

IS - 6

ER -